Veru is expected to report a consensus revenue of $3.15 million and an EPS loss of -$0.34 for the fiscal quarter ending June 30, 2026, while the current stock price of $1.18 sits significantly below the $3.50 average analyst price target. Investors are primarily focused on clinical updates regarding the Phase 2b enobosarm trial for muscle preservation in GLP-1 weight loss patients.
Management's commentary on the cash runway and the potential for a strategic partnership remains a critical factor for the stock's performance. Recent volatility reflects the high-stakes nature of the enobosarm clinical readout, which is viewed as the company's primary value driver following the decline in FC2 product sales.